Park Y C, Kiwamoto H, Nishioka T, Tsujihashi H, Mitsubayashi S, Matsuura T, Akiyama T, Kurita T, Miyamoto T
Department of Urology, School of Medicine, Kinki University.
Hinyokika Kiyo. 1987 Jun;33(6):883-8.
Combined measurement of serum prostate-specific antigen (PA) and prostatic acid phosphatase (PAP) was performed in 235 patients with various urologic diseases including 55 patients with prostatic cancer. A PA level of over 24.7 ng/ml and a PAP level of over 3.1 ng/ml were considered to be positive. The positive rate of PA was 57% in the patients with untreated prostatic cancer and 3% in the patients without prostatic cancer. The positive rate of PAP was 52% in the patients with untreated prostatic cancer and 1% in the patients without prostatic cancer. PA and PAP were considered to be equally sensitive and specific serum markers of prostatic cancer. However, the positive rate increased to 65% without increasing the false positive rate when the PA and PAP were both measured simultaneously. The combined assay of PA and PAP is recommended for screening prostatic cancer. The cross-over titer of PA and gamma-Sm using standard samples in each kit revealed linearity, which suggested that PA and gamma-Sm possess the same antigenicity.
对235例患有各种泌尿系统疾病的患者进行了血清前列腺特异性抗原（PA）和前列腺酸性磷酸酶（PAP）的联合检测，其中包括55例前列腺癌患者。PA水平超过24.7 ng/ml且PAP水平超过3.1 ng/ml被视为阳性。未治疗的前列腺癌患者中PA的阳性率为57%，无前列腺癌的患者中为3%。未治疗的前列腺癌患者中PAP的阳性率为52%，无前列腺癌的患者中为1%。PA和PAP被认为是前列腺癌同样敏感和特异的血清标志物。然而，当同时检测PA和PAP时，阳性率提高到65%，且假阳性率未增加。推荐联合检测PA和PAP用于前列腺癌筛查。使用每个试剂盒中的标准样品对PA和γ-Sm进行交叉效价测定显示出线性关系，这表明PA和γ-Sm具有相同的抗原性。
